Heterozygous deletion of chromosome 17p renders prostate cancer vulnerable to inhibition of RNA polymerase II
Heterozygous deletion of chromosome 17p (17p) is one of the most frequent genomic
events in human cancers. Beyond the tumor suppressor TP53, the POLR2A gene encoding …
events in human cancers. Beyond the tumor suppressor TP53, the POLR2A gene encoding …
RB1 loss overrides PARP inhibitor sensitivity driven by RNASEH2B loss in prostate cancer
C Miao, T Tsujino, T Takai, F Gui, T Tsutsumi… - Science …, 2022 - science.org
Current targeted cancer therapies are largely guided by mutations of a single gene, which
overlooks concurrent genomic alterations. Here, we show that RNASEH2B, RB1, and …
overlooks concurrent genomic alterations. Here, we show that RNASEH2B, RB1, and …
Androgen receptor splicing variant 7 (ARv7) promotes DNA damage response in prostate cancer cells
H Luo, Y Liu, Y Li, C Zhang, B Yu… - The FASEB Journal, 2022 - Wiley Online Library
In the treatment of patients with locally advanced prostate cancer (PCa), androgen
deprivation therapy (ADT) significantly enhances the efficacy of radiotherapy by weakening …
deprivation therapy (ADT) significantly enhances the efficacy of radiotherapy by weakening …
Diverse AR-V7 cistromes in castration-resistant prostate cancer are governed by HoxB13
The constitutively active androgen receptor (AR) splice variant 7 (AR-V7) plays an important
role in the progression of castration-resistant prostate cancer (CRPC). Although biomarker …
role in the progression of castration-resistant prostate cancer (CRPC). Although biomarker …
HoxB13 mediates AR-V7 activity in prostate cancer
HI Navarro, AS Goldstein - Proceedings of the National …, 2018 - National Acad Sciences
Prostate cancer remains a leading cause of cancer death in the United States (1). In 2017, it
was estimated that over 160,000 prostate cancer cases were diagnosed in the United …
was estimated that over 160,000 prostate cancer cases were diagnosed in the United …
Identification of the epigenetic reader CBX2 as a potential drug target in advanced prostate cancer
PL Clermont, F Crea, YT Chiang, D Lin, A Zhang… - Clinical …, 2016 - Springer
Background While localized prostate cancer (PCa) can be effectively cured, metastatic
disease inevitably progresses to a lethal state called castration-resistant prostate cancer …
disease inevitably progresses to a lethal state called castration-resistant prostate cancer …
[HTML][HTML] Tumor suppressor role of RBM22 in prostate cancer acting as a dual-factor regulating alternative splicing and transcription of key oncogenic genes
JM Jiménez-Vacas, AJ Montero-Hidalgo… - Translational …, 2023 - Elsevier
Prostate cancer (PCa) is one of the leading causes of cancer-related deaths among men.
Consequently, the identification of novel molecular targets for treatment is urgently needed …
Consequently, the identification of novel molecular targets for treatment is urgently needed …
Targeting a splicing-mediated drug resistance mechanism in prostate cancer by inhibiting transcriptional regulation by PKCβ1
The androgen receptor (AR) is a central driver of aggressive prostate cancer. After initial
treatment with androgen receptor signaling inhibitors (ARSi), reactivation of AR signaling …
treatment with androgen receptor signaling inhibitors (ARSi), reactivation of AR signaling …
A genome-wide CRISPR activation screen identifies PRRX2 as a regulator of enzalutamide resistance in prostate cancer
Y Rodríguez, K Unno, MI Truica, ZR Chalmers, YA Yoo… - Cancer research, 2022 - AACR
Androgen receptor (AR) pathway inhibitors are the mainstay treatment for advanced prostate
cancer, but resistance to therapy is common. Here, we used a CRISPR activation screen in …
cancer, but resistance to therapy is common. Here, we used a CRISPR activation screen in …
Copy number loss of 17q22 is associated with enzalutamide resistance and poor prognosis in metastatic castration-resistant prostate cancer
Purpose: The purpose of this study was to measure genomic changes that emerge with
enzalutamide treatment using analyses of whole-genome sequencing and RNA …
enzalutamide treatment using analyses of whole-genome sequencing and RNA …
相关搜索
- ar v7 prostate cancer
- enzalutamide resistance prostate cancer
- heterozygous deletion chromosome 17p
- rna polymerase chromosome 17p
- rna polymerase heterozygous deletion
- prostate cancer chromosome 17p
- rna polymerase prostate cancer
- prostate cancer drug target
- heterozygous deletion prostate cancer
- prostate cancer rnaseh2b loss
- prostate cancer dual factor
- prostate cancer epigenetic reader
- prostate cancer transcriptional regulation
- prostate cancer poor prognosis
- prostate cancer copy number loss
- prostate cancer rb1 loss